Search Results
Your search for ,wHo matches 21253 pages
Showing 1301 - 1350Only Half of Young Adults With Cancer Are Told of Fertility Preservation Options by Their Providers: Strategies for Improving That Number
Each year in the United States, approximately 90,000 adolescents and young adults (AYAs), defined as those between the ages of 15 and 39, are diagnosed with cancer, and about 9,300 die of the disease.1 Worldwide, the number of new cases of cancer in this age population tops 1,300,200—an increase of ...
FDA Approves Mirdametinib for Neurofibromatosis Type 1
On February 11, the U.S. Food and Drug Administration approved mirdametinib (Gomekli), a kinase inhibitor, for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. ReNeu Trial...
Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup
An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...
Mobile Prostate Cancer Screening Clinic Was Effective in Detecting Prostate Cancer in Underserved Men
Globally, prostate cancer is the second most frequently diagnosed cancer and the fifth-leading cause of cancer-related death among men—and the leading cause of cancer-related death in Central America and sub-Saharan Africa. Four years ago, British researchers launched the “Man Van” pilot mobile...
Survey Finds More Than Half of Oncologists Are Experiencing Professional Burnout
In JCO Oncology Advances, Schenkel et al published the results of an ASCO survey measuring professional well-being, satisfaction, and the effect of both on career plans among oncologists in the United States. The analysis revealed a higher rate of burnout compared with that observed a decade ago....
In Case You Missed It: Additional Studies of Interest From ASH 2024
A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...
Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials
The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...
Adjuvant T-DM1 vs Trastuzumab for Residual HER2-Positive Breast Cancer: Overall Survival in KATHERINE
As reported in The New England Journal of Medicine by Geyer et al, interim analysis of overall survival in the phase III KATHERINE trial showed a significant benefit of ado-trastuzumab emtansine (T-DM1) vs trastuzumab in patients with residual invasive HER2-positive breast cancer after neoadjuvant...
Pertuzumab Retreatment in HER2-Positive Locally Advanced/Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Yamamoto et al, the final overall survival analysis of the Japanese phase III PRECIOUS study showed a significant benefit with the addition of pertuzumab retreatment to trastuzumab plus physician’s choice of chemotherapy (PTC) in patients with...
Using AI to Identify Treatment Options for Castleman Disease
A novel artificial intelligence (AI) tool uncovered an effective treatment for a patient with idiopathic multicentric Castleman’s disease, according to a recent study published by Mumau et al in The New England Journal of Medicine. Background Idiopathic multicentric Castleman’s disease is a rare...
Is Thyroid Cancer Overdiagnosed?
A retrospective study provides new evidence that thyroid cancer continues to be overdiagnosed and that aggressive screening and treatment of thyroid cancer has not led to higher survival rates. The research was published by Chen et al in The Lancet Diabetes & Endocrinology. “Many studies have...
Survival Outcomes in Patients With ERBB2-Positive Metastatic Breast Cancer With CNS Involvement
In a retrospective cohort study from Memorial Sloan Kettering Cancer Center, which was reported in JAMA Network Open, Ferraro et al found that patients with ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial...
Triplet for Untreated TP53-Mutated Mantle Cell Lymphoma
First-line treatment with the Bruton’s tyrosine kinase inhibitor zanubrutinib plus the anti-CD20 monoclonal antibody obinutuzumab and the BCL2 inhibitor venetoclax appeared to be safe and active in previously untreated patients with TP53-mutated mantle cell lymphoma, based on the results of the...
CAR T-Cell Therapy Not Linked to Secondary Cancers, Study Finds
Researchers have found no evidence that chimeric antigen receptor (CAR) T-cell therapy caused secondary cancers in the modified T cells, according to a recent study published by Jadlowsky et al in Nature Medicine. Background CAR T-cell therapy is a personalized type of immunotherapy that employs...
Potential Link Between Early Side Effects From Radiation Therapy and Long-Term Side Effects in Patients With Prostate Cancer
The risk of developing more serious long-term urinary and bowel health issues may be higher in men undergoing radiation therapy for prostate cancer who experience side effects early in treatment, according to a recent study published by Nikitas et al in The Lancet Oncology. The findings highlighted ...
Discontinuation and Resumption of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
As reported in the Journal of Clinical Oncology by Mascarenhas et al, follow-up of a cohort of pediatric patients with TRK fusion sarcomas and related mesenchymal tumors treated with larotrectinib showed that discontinuation of treatment—with resumption for progressive disease—was associated with...
Neoadjuvant Radiotherapy May Hamper Immunotherapy Response in Patients With Breast Cancer
Researchers have provided novel insights into the effects of radiation on the immune cells surrounding breast cancer tumors, according to a recent study published by Yoneyama et al in the International Journal of Radiation Oncology • Biology • Physics. The findings revealed that the relationship...
Adjuvant Chemotherapy After Preoperative mFOLFIRINOX and Resection of Localized Pancreatic Adenocarcinoma
In a retrospective cohort study reported in JAMA Oncology, Stoop et al found that use of adjuvant modified leucovorin, fluorouracil, irinotecan, and oxaliplatin (mFOLFIRINOX) and other multiagent chemotherapy regimens improved overall survival vs no adjuvant chemotherapy in patients with localized...
Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL
A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...
FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd
The U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone receptor (HR)-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with fam-trastuzumab...
Can R-CHOP–Like Therapy Effectively Treat Late-Relapse DLBCL?
Late relapse of diffuse large B-cell lymphoma (DLBCL) may represent a new lymphoma arising from a common precursor cell that is essentially chemotherapy-naive. Treatment with curative intent using a second-line regimen like R-CHOP (rituximab cyclophosphamide, doxorubicin, prednisone, and...
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Two pivotal phase III trials presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition mark a significant shift toward chemotherapy-free approaches in chronic lymphocytic leukemia (CLL), offering potentially more effective and tolerable treatment options for both...
Salpingectomy During Other Abdominal Surgeries May Lower Ovarian Cancer Risk
Fallopian tube removal performed during other abdominal surgeries could reduce the risk of ovarian cancer incidence among women who have already completed their families, according to a recent study published by Kather et al in PLOS Medicine. Background Ovarian cancer is the third most common...
Does Brain MRI Surveillance Benefit Asymptomatic Patients With Stage IV Breast Cancer?
Researchers have found that asymptomatic brain metastases may be more common in patients with stage IV breast cancer than previously understood, according to a recent study published by Ahmed et al in Neuro-Oncology. The findings suggest that physicians may need to reconsider current screening...
CheckMate 7FL: Neoadjuvant Immunochemotherapy in ER-Positive, HER2-Negative Breast Cancer
A phase III trial has shown adding the PD-1 inhibitor nivolumab to anthracycline- and taxane-based chemotherapy that patients receive ahead of surgery may improve breast cancer cure rates. CheckMate-7FL involved 510 patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer,...
Tiragolumab Plus Atezolizumab/Bevacizumab in Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma
In a phase Ib-II study (MORPHEUS-Liver) reported in The Lancet Oncology, Finn et al found that the addition of tiragolumab, an anti-TIGIT monoclonal antibody, to atezolizumab/bevacizumab improved objective response rate in patients with unresectable, locally advanced, or metastatic hepatocellular...
Talimogene Laherparepvec May Effectively Reduce Basal Cell Carcinoma Size Prior to Surgical Resection
Treatment with the oncolytic virus talimogene laherparepvec may be effective in patients with basal cell carcinoma, according to a novel study published by Ressler et al in Nature Cancer. Background Although basal cell carcinoma—which typically occurs in chronically sun-exposed areas such as the...
Fecal Microbiota Transplantation Following ASCT
Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...
BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis
The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...
Case 2: Moderate Chronic GVHD
This is Part 2 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the management of moderate...
Case 1: Acute GVHD in a Patient With Lymphoma
This is Part 1 of Treatment Sequencing Considerations for Chronic Graft-vs-Host Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Corey Cutler, Betty K. Hamilton, and Hannah K. Choe discuss the first-line treatment of...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Early-Stage Classic Hodgkin Lymphoma
“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.” —Muhammad Ali Long-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of...
T-DXd Approved by the FDA for Pretreated Patients With HER2-Low or -Ultralow Metastatic Breast Cancer
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ...
Clearance of Driver Mutations after Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis
In a German single-center study reported in The New England Journal of Medicine, Gagelmann et al determined that clearance of driver mutations after allogeneic hematopoietic stem-cell transplantation was associated with better outcomes in patients with myelofibrosis. Study Details The study...
Pinpointing Contributing Factors in Response to Posttransplant Donor Lymphocyte Infusion in Patients With AML
Researchers have identified factors that could determine whether donor lymphocyte infusion—a type of adoptive cell therapy—will result in remission among patients with acute myeloid leukemia (AML) who have relapsed following allogeneic hematopoietic stem cell transplant (HSCT), according to a...
Novel Combination Targeted Therapies, Chemotherapy in BRAF-Mutated Metastatic Colorectal Cancer
First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings presented by Kopetz et ...
New Findings on Aspirin and Risk of Colorectal Cancer Recurrence
According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...
New Research Explores Blood Test to Determine Prognosis, Benefit of Celecoxib in Stage III Colon Cancer
Previous research has shown that nonsteroidal antiinflammatory drugs (NSAIDs), including aspirin and COX-2 inhibitors, may reduce the risk of developing colon cancer. A recent CALGB/SWOG study revealed that adding celecoxib to FOLFOX chemotherapy improved disease-free survival in patients with...
EULAR: Balancing Treatment Risks for Inflammatory Arthritis and Cancer
The European Alliance of Associations for Rheumatology (EULAR) introduced new points to consider surrounding the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer, according to recent recommendations published by Sebbag et al in the Annals of the...
Muscular Strength, Cardiorespiratory Fitness May Be Linked to Lower Risk of Mortality in Patients With Cancer
Muscular strength and cardiorespiratory fitness may be associated with a lower risk of all-cause mortality in patients with cancer, according to a recent study published by Bettariga et al in the British Journal of Sports Medicine. The findings indicated that a tailored exercise regimen may improve ...
Some Patients With Low-Risk Ductal Carcinoma In Situ May Be Able to Avoid Surgery
Active monitoring appears to be a safe strategy for the management of some patients with low-risk ductal carcinoma in situ (DCIS), proving noninferior to guideline-concordant management of this patient population (ie, surgery with or without radiation therapy). After 2 years, the rate of invasive...
Getting a Lung Cancer Diagnosis Was Shocking
For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...
AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma
Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...
AALL1731 Trial: Adding Blinatumomab to Standard Chemotherapy Improves Outcomes in Pediatric B-Cell ALL
Results of a phase III study suggest that the addition of the immunotherapy agent blinatumomab—a bispecific T-cell engager targeting CD19—to standard chemotherapy may help to prevent relapse in more children with B-cell acute lymphoblastic leukemia (B-ALL), the most common pediatric cancer,...
Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...
Everolimus/Lanreotide vs Everolimus in Gastroenteropancreatic Neuroendocrine Tumors
A recent study found that a combination of the mTOR inhibitor everolimus and the hormone-blocking drug lanreotide extended progression-free survival compared with everolimus alone for people with some types of neuroendocrine tumors in the pancreas or gastrointestinal tract. The research will be...
Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?
Colorectal cancer is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease. Although screening for the cancer through colonoscopy or sigmoidoscopy is effective in detecting the disease, nearly...
New Study Identifies Potential Dose-Dependent Relationship Among Alcohol Consumption, HBV-Associated Cirrhosis, Hepatocellular Carcinoma
Investigators may have established a dose-dependent model of alcohol consumption on the risks of hepatitis B virus (HBV)-associated cirrhosis and hepatocellular carcinoma, according to a recent study published by Wu et al in the Journal of Clinical and Translational Hepatology. The quantitative...
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI
ASCO has applauded Monica M. Bertagnolli, MD, FASC, FASCO, for her service as the 17th Director of the National Institutes of Health (NIH) and Kimryn Rathmell, MD, PhD, for her work as the 17th Director of the National Cancer Institute (NCI). “ASCO would like to extend our deepest gratitude to Dr....
